On a relative basis, the stock has outperformed the S&P 500 by 4.06% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.7% in the last 1 week, and is up 8.61% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.28% and the 50-Day Moving Average is 5.79%.
Eli Lilly and Company (NYSE:LLY): The stock opened at $80.98 on Friday but the bulls could not build on the opening and the stock topped out at $81.00 for the day. The stock traded down to $79.94 during the day, due to lack of any buying support eventually closed down at $80.22 with a loss of -0.46% for the day. The stock had closed at $80.59 on the previous day. The total traded volume was 4,529,123 shares.
The company Insiders own 0.2% of Eli Lilly and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1% . Institutional Investors own 76.18% of Eli Lilly and Company shares. During last six month period, the net percent change held by insiders has seen a change of -1.3%. In a related news, The officer (Chief Eth/Cmpl Ofcr & SVP, ERM), of Lilly Eli & Co, Barnes Melissa S had unloaded 992 shares at $73.77 per share in a transaction on June 10, 2016. The total value of transaction was $73,180. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.